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EDITORIAL
Hepatocellular  Carcinoma:  Portuguese  Data  in  Chronic
Hepatitis B Patients  on  Antiviral  Therapy  and
Treatment Results  With  Sorafenib
Carcinoma  Hepatocelular:  Dados  Portugueses  de  Doentes  com  Hepatite  B
Crónica  sob  Terapêutica  Antiviral  e  do  Tratamento  com  Sorafenib
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tLiver  cancer  is  the  ﬁfth  most  common  malignant  tumor
in  men  and  the  ninth  in  women.  An  estimated  782,500
new  cases  occurred  in  the  world  during  2012.1 Most  pri-
mary  liver  cancers  worldwide  are  hepatocellular  carcinoma
(HCC),  which  likely  accounts  for  70--90%  of  cases.  Globally  it
is  the  second  leading  cause  of  cancer  death  in  men  and  the
sixth  among  women,  with  about  745,500  deaths  in  2012.1 It
is  one  of  the  most  fatal  cancers,  with  ﬁve-year  survival  rates
less  than  20%  even  in  developed  countries.
HCC  incidence  is  increasing  in  areas  with  historically
low  rates,  including  parts  of  Oceania,  Western  Europe,  and
Northern  America.  In  the  United  States,  age-adjusted  inci-
dence  rates  of  liver  cancer  more  than  tripled  between  1975
and  2011.2
This  increase  is  thought  to  be  attributable  to  chronic
hepatitis  C  virus  (HCV)  infection,  mainly  due  to  injection
drug  abuse,  which  was  common  in  the  1960s  and  1970s,  and
also  to  increases  in  the  prevalence  of  obesity  and  diabetes
mellitus.3,4 In  Portugal,  Marinho  et  al.  revealed  a  2.9-fold
increase  in  hospital  admissions  for  HCC  in  the  twelve  years
studied  (1993--2005),  reaching  834  hospital  admissions  in
2005  (8.6/105).5
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HBV)  or  HCV  infections.  Other  risk  factors  include  alcoholic
irrhosis  (very  important  in  our  country),  smoking,  type  2
iabetes,  and/or  non-alcoholic  fatty  liver  disease  (associ-
ted  with  obesity).
The  primary  causes  of  HCC  can  be  prevented  through  pub-
ic  health  measures,  which  include  avoiding  smoking  and  lim-
ting  alcohol  consumption,  HBV  vaccination,  sanitary  medi-
al  practices,  healthy  lifestyle  choices,  and  environmental
anagement  strategies.  A  vaccine  that  protects  against  HBV
as  been  available  since  1982,  and  proved  to  be  also  an
nti-tumoral  vaccine.  While  there  is  no  vaccine  available
o  protect  against  HCV,  new  antiviral  therapies  may  prevent
hronic  infection  among  those  with  acute  (new)  infection.
he  United  States  Center  for  Disease  Control  and  Preven-
ion  recommends  a  one-time  test  for  HCV  infection  for  all
dults  born  between  1945  and  1965,  since  people  in  this
irth  cohort  account  for  three  quarters  of  both  HCV-infected
ndividuals  and  HCV-related  deaths  in  the  United  States.6
Among  individuals  with  chronic  viral  hepatitis,  a  reduc-
ion  in  the  progression  of  liver  ﬁbrosis,  or  even  its  regression,
nd  also  a reduction  in  the  risk  of  liver  cancer,  has  been
hown  with  the  use  of  antiviral  treatments,  mainly  in  HCV,
ut  probably  also  in  HBV  infection.4,7 Nevertheless,  main-
ained  surveillance  of  HCC  occurrence  is  recommended  in
ppropriate  patients  by  the  international  guidelines.
Magalhães-Costa  et  al.  publish  in  this  issue  of  GE  a
aper  which  investigates  HCC  incidence,  risk  factors  and
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he  performance  of  baseline  Risk  estimation  for  hepatocel-
ular  carcinoma  (REACH-B)  score  in  a  Portuguese  population
ith  chronic  hepatits  B  on  antiviral  therapy.  They  retro-
pectively  studied  one  hundred  and  twenty  patients  treated
ith  tenofovir  or  entecavir  for  at  least  12  months.  The  cal-
ulated  cumulative  incidence  rates  of  HCC  at  1,  3  and  5
ears  on  therapy  were  5.1%,  7.3%  and  8.8%,  respectively.  Old
ge,  excessive  alcohol  intake  and  cirrhosis  were  the  most
mportant  risk  factors  associated  with  HCC  onset.  The  dis-
riminatory  performance  of  baseline  REACH-B  score  in  those
ortuguese  patients  was  limited.  The  authors  concluded  that
ontinued  surveillance  is  recommended  for  CHB  patients  on
ntiviral  therapy.
In  accordance  with  BCLC  classiﬁcation,  early  stage  HCC
an  be  treated  with  surgery,  hepatic  resection  being  the
reatment  of  choice  for  no  cirrhotic  HCC  patients,  and  liver
ransplantation  is  recommended  for  patients  with  early  HCC
ot  suitable  for  resection  (e.g.,  multifocal  small  tumors,
irrhosis  with  severe  liver  dysfunction).  Other  effective
reatments  include  local  ablation  therapy,  like  radio  fre-
uency  ablation,  used  in  patients  with  early-stage  HCC  who
re  not  suitable  for  surgical  treatment,  and  transarterial
hemoembolization,  indicated  for  intermediate-stage  unre-
ectable  HCC  with  no  vascular  invasion  or  extra  hepatic
pread.  Radioembolization  (internal  radiation  therapy)  using
0Y-labeled  glass  or  resin  microspheres  is  also  available  in
ome  referral  centers  for  treating  unresectable  HCC.  How-
ver,  comparative  data  among  these  therapies  is  lacking.
For  patients  with  advanced  stage  HCC  or  those  who
rogress  after  loco-regional  therapies,  sorafenib  is  the  best
vailable  therapy.  It  is  an  oral  multikinase  inhibitor  that
ncreases  apoptosis  and  reduces  cell  proliferation  and  angio-
enesis,  approved  in  2007  for  the  treatment  of  HCC  in
atients  who  are  not  candidates  for  surgery  or  local  ablation
nd  do  not  have  severe  cirrhosis.
Cardoso  et  al.  publish  in  this  issue  of  GE  the  experience  of
6  HCC  Portuguese  patients  treated  with  sorafenib  and  con-
lude  that  the  main  factor  of  prognosis  identiﬁed,  beyond
hildPugh  class  and  BCLC  stage  was  the  occurrence  of  sig-
iﬁcant  adverse  events  (AEs).
Several  studies  on  sorafenib  also  support  the  observa-
ion  that  the  occurrence  of  clinically  relevant  AEs  (grade
2  according  to  NCI-CTCAE  scale),  especially  hypertension,
iarrhea  and  skin  lesions8--12 are  associated  with  higher
hances  of  tumor  response  and  therefore  survival  improve-
ent.
So,  according  to  some  authors,  AEs  may  represent  a
urrogate  of  response  and  be  associated  with  a  favorable
utcome,  encouraging  sorafenib  continuation  rather  than  its
nterruption.In  a  very  recent  prospective  study13 seeking  to  measure
he  efﬁcacy  of  a  sorafenib  dose  reduction  regimen,  adjusted
n  patient’s  tolerability,  and  aimed  at  increasing  the  expo-
ure  to  the  drug,  the  authors  concluded  that  in  patients  with
1A.  Simão
dvanced  hepatocellular  carcinoma,  sorafenib  dose  adjust-
ents  based  on  inducing  tolerability  of  relevant  AEs  prolong
rug  exposure  and  maximize  survival.
The  two  studies  published  in  this  issue  of  GE  underline,  as
ey  messages,  the  importance  of  HCC  surveillance,  even  in
hronic  hepatitis  B  patients  on  successful  antiviral  therapy,
nd  the  beneﬁts  of  sorafenib  in  the  treatment  of  advanced
CC,  with  the  best  results  being  probably  obtained  in  cases
ith  AEs  that  do  not  preclude  maintenance  of  therapy.
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